CHICAGO, Dec. 02, 2025 (GLOBE NEWSWIRE) -- Quetzal Therapeutics, a biopharmaceutical company specializing in developing transformative treatments for rare diseases,…
SOLAIRIA-1 and SOLAIRIA-2 will evaluate GB-0895 in approximately 1,600 patients with severe asthma whose disease remains inadequately controlled on current…
New name reflects company’s transformation as it advances toward the final phase of Lybrido™’s clinical development The Arletta butterfly symbolism…
The Company continues working with the third-party manufacturer to address recent FDA follow-up information requests which are required to lift…
Elevates Co-Founder Dhruv Shringi to Executive Chairman; Appoints Siddhartha Gupta as CEONEW DELHI, Nov. 25, 2025 /PRNewswire/ -- Yatra Online…
- Results Underscore Need for Continued Research and Diverse Treatment PipelineCHICAGO, Nov. 24, 2025 /PRNewswire/ -- The Alzheimer's Association is disappointed…
SHANGHAI, Nov. 24, 2025 (GLOBE NEWSWIRE) -- Shanghai Junshi Biosciences Co., Ltd (Junshi Biosciences, HKEX: 1877; SSE: 688180), a leading…
Largest prospective clinical trial to-date in a rare subtype of GIST ROCKVILLE, Md. and SUZHOU, China, Nov. 24, 2025 (GLOBE…
November 18, 2025 16:30 ET | Source: Protara Therapeutics NEW YORK, Nov. 18, 2025 (GLOBE NEWSWIRE) -- Protara Therapeutics, Inc.…
Testing of the GMR-001 Hypercar entered a new phase last week at Circuit Magny-Cours in France where Genesis Magma Racing…